# Shield Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shield-diagnostics

- Industry: Biotechnology
- Headquarters: San Jose, US
- Total disclosed funding: $8.8M
- Latest round: Series A (May 11, 2018)
- Investors on record: 4

## About

Founded in 2016 and based in California, US, Shield Diagnostics Corp., aka Shield Bio, is a company designed to combat the global threat of antibiotic resistance and revolutionizing infectious disease treatment. Fred Turner and Sam Parlett are the co-founders of the company.

The company's primary focus is the development of rapid and accurate molecular antibiotic susceptibility testing through its Target-X platform. The firm’s cutting-edge technology enables swift and precise identification of the infectious agent and associated antibiotic susceptibility genes, eliminating the need for time-consuming culture tests. Shield Bio's flagship product, Target-NG, focuses on identifying the sensitivity of N. gonorrhoeae infections to ciprofloxacin.

## Funding rounds

- Series A, May 11, 2018, $5.3M — Argonautic Ventures
- Seed, Feb 8, 2017, $3.4M — Andreessen Horowitz, Y Combinator, Refactor Capital

## Investors

- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Seed
- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed
- Refactor Capital (https://capitalatlas.ai/funds/refactor-capital) — Seed
- Argonautic Ventures (https://capitalatlas.ai/funds/argonautic-ventures) — Series A